skip to primary navigationskip to content
 

Professor Gordon Dougan FMedSci, FRS

Professor Gordon Dougan, FMedSci, FRS

Head of Pathogen Research

Gordon Dougan is accepting applications for PhD students.

Gordon Dougan is available for consultancy.


Departments

Wellcome Trust Sanger Institute:
Head of the Microbial Pathogenesis group
Department of Medicine:

Research Interests

Professor Gordon Dougan's research focuses on the genetic analysis of host/pathogen interactions during infection, particularly those involving enteric bacteria. He has worked extensively in both academia and industry, making important contributions in the field of vaccinology where he has worked to improve vaccine delivery to poorly resourced regions.

Gordon Dougan is an expert in vaccinology/pathogenic mechanisms, specialising on the immunology of mucosal vaccines and molecular basis of infection. His group exploit genomic approaches to study host-pathogen interactions and the analysis of microbial populations.

Gordon has extensive teaching experience at both the undergraduate and postgraduate level. He has served on several editorial boards and regularly reviews manuscripts for high-impact journals. He is a consultant for industry and has founded biotechnology companies, including the single-chain antibody company VHSquared.

Gordon is a Fellow of the Royal Society, the Biology Society, the Academy of Medical Sciences and is an EMBO (European Molecular Biology Organization) member. He established the Centre for Molecular Microbiology and Infection (including a raising funding for a building) at Imperial College London and was the Board of Management representative for Pathogen Research for ten years (2004-2014) at the Sanger Institute where he is currently a Senior Group Leader.

Gordon worked for more than ten years for the multi-national pharmaceutical company, The Wellcome Foundation, which is now part of GSK. During this period he became Head of Molecular Biology, managing teams working on vaccines, humanised antibodies and scale-up systems. He contributed to the discovery of pertactin as a key protective antigen for acellular whooping cough vaccines and is now an advisor for many companies, serving as an Scientific Advisory Board (SAB) or Board member. Gordon was Chair of the SAB for Novartis Vaccines & Diagnostics for more than ten years and helped found the Novartis Vaccine Global Health Institute (NVGH).
He is currently on the board of The Hilleman Laboratories, a joint enterprise between Merck and The Wellcome Trust and has founded spin-out companies and served as a Trustee at the International Vaccine Institute in Korea. Gordon is also currently an SAB member for ICDDR-B (International Centre for Diarrhoeal Disease Research, Bangladesh) and has served as a member of several WHO (World Health Organization) Committees.

Keywords

vaccines ; genomics ; genetics

Topics

  • salmonellosis
  • cholera
  • influenza
  • vaccines

Key Publications

Jacqueline K. White, Anna-Karin Gerdin, Natasha A. Karp, Ed Ryder, Marija Buljan, James N. Bussell, Jennifer Salisbury, Simon Clare, Neil J. Ingham, Christine Podrini, Richard Houghton, Jeanne Estabel, Joanna R. Bottomley, David G. Melvin, David Sunter, Niels C. Adams, The Sanger Institute Mouse Genetics Project, David Tannahill, Darren W. Logan, Daniel G. MacArthur, Jonathan Flint, Vinit B. Mahajan, Stephen H. Tsang, Ian Smyth, Fiona M. Watt, William C. Skarnes, Gordon Dougan, David J. Adams, Ramiro Ramirez-Solis, Allan Bradley, Karen P. Steel Genome-wide Generation and Systematic Phenotyping of Knockout Mice Reveals New Roles for Many Genes
Cell. 2013 July 18; 154(2): 452–464.

Okoro CK, Kingsley RA, Connor TR, Harris SR, Parry CM, Al-Mashhadani MN, Kariuki S, Msefula CL, Gordon MA, de Pinna E, Wain J, Heyderman RS, Obaro S, Alonso PL, Mandomando I, Maclennan CA, Tapia MD, Levine MM, Tennant SM, Parkhill J, Dougan G. Intracontinental spread of human invasive Salmonella Typhimurium pathovariants in sub-Saharan Africa. Nat Genet. 2012 Sep 30.  

Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, Chin CR, Feeley EM, Sims JS, Adams DJ, Wise HM, Kane L, Goulding D, Digard P, Anttila V, Baillie JK, Walsh TS, Hume DA, Palotie A, Xue Y, Colonna V, Tyler-Smith C, Dunning J, Gordon SB; GenISIS Investigators; MOSAIC Investigators, Smyth RL, Openshaw PJ, Dougan G, Brass AL, Kellam P. IFITM3 restricts the morbidity and mortality associated with influenza. Nature. 2012 Mar 25;484(7395):519-23.  

Wang W, Hale C, Goulding D, Haslam SM, Tissot B, Lindsay C, Michell S, Titball R, Yu J, Toribio AL, Rossi R, Dell A, Bradley A, Dougan G.  Mannosidase 2, alpha 1 deficiency is associated with ricin resistance in embryonic stem (ES) cells. PLoS One. 2011;6(8)

Mutreja A, Kim DW, Thomson NR, Connor TR, Lee JH, Kariuki S, Croucher NJ, Choi SY, Harris SR, Lebens M, Niyogi SK, Kim EJ, Ramamurthy T, Chun J, Wood JL, Clemens JD, Czerkinsky C, Nair GB, Holmgren J, Parkhill J, Dougan G. Evidence for several waves of global transmission in the seventh cholera pandemic. Nature. 2011 Aug 24;477(7365):462-5. 
 

Dougan G, John V, Palmer S, Mastroeni P. Immunity to salmonellosis. Immunol Rev. 2011 Mar;240(1):196-210. Review.

Croucher NJ, Harris SR, Fraser C, Quail MA, Burton J, van der Linden M, McGee L, von Gottberg A, Song JH, Ko KS, Pichon B, Baker S, Parry CM, Lambertsen LM, Shahinas D, Pillai DR, Mitchell TJ, Dougan G, Tomasz A, Klugman KP, Parkhill J, Hanage WP, Bentley SD. 
Rapid pneumococcal evolution in response to clinical interventions. Science. 2011 Jan 28;331(6016):430-4.